Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells

Graphical abstract

Authors
Cristian R. Smulski, Luyao Zhang, Malte Burek, ..., Marta Rizzi, Hermann Eibel, Pascal Schneider

Correspondence
pascal.schneider@unil.ch (P.S.), cristian.smulski@cab.cnea.gov.ar (C.R.S.)

In brief
Smulski et al. characterize immunodeficiency-associated mutations in the transmembrane domain of TACI that perturb the complex self-assembly of this receptor, impinging on auto- or ligand-induced signaling. Oligomerization of the transmembrane domain of TACI plays an active role in the proliferation of activated B cells and in antibody production.

Highlights
- TACI transmembrane domain associates via distinct trimeric and dimeric interfaces
- CVID-associated mutation A181E and C172Y affect the trimeric and dimeric interfaces
- TACI transmembrane domain regulates ligand-dependent and -independent signaling
- Spontaneous TACI signals help proliferation and IgA production of activated B cells
Article

Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells

Cristian R. Smulski,1,2,3,* Luyao Zhang,2 Malte Burek,2 Ariadna Teixidó Rubio,2 Jana-Susann Briem,2 Mauricio P. Sica,3,4 Eirini Sevdali,2 Michele Vigolo,1 Laure Willen,1 Patricia Odermatt,2 Duygu Istanbullu,2 Stephanie Herr,2 Marco Cavallari,5 Henry Hess,1 Marta Rizzi,2 Hermann Eibel,2,7 and Pascal Schneider1,7,8,*

1Department of Biochemistry, University of Lausanne, Ch. des Boveresses 155, 1066 Epalinges, Switzerland
2Faculty of Medicine and Medical Center, University of Freiburg, Department of Rheumatology and Center for Chronic Immunodeficiency, Breisacherstr. 115, 79106 Freiburg, Germany
3Medical Physics Department, Centro Atómico Bariloche, Comisión Nacional de Energía Atómica (CNEA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Avenida E- Bustillo 9500, R8402AGP Río Negro, San Carlos de Bariloche, Argentina
4Instituto de Energía y Desarrollo Sustentable, Centro Atómico Bariloche, Comisión Nacional de Energía Atómica (CNEA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Avenida E- Bustillo 9500, R8402AGP Río Negro, San Carlos de Bariloche, Argentina
5BIOSS Centre for Biological Signalling Studies, University of Freiburg, Schänzlestr. 18, 79104 Freiburg, Germany
6Merck KGaA, D-64293 Darmstadt, Germany
7Senior authors
8Lead contact
*Correspondence: pascal.schneider@unil.ch (P.S.), cristian.smulski@cab.cnea.gov.ar (C.R.S.)

https://doi.org/10.1016/j.celrep.2022.110583

SUMMARY

In mature B cells, TACI controls class-switch recombination and differentiation into plasma cells during T cell-independent antibody responses. TACI binds the ligands BAFF and APRIL. Approximately 10% of patients with common variable immunodeficiency (CVID) carry TACI mutations, of which A181E and C172Y are in the transmembrane domain. Residues A181 and C172 are located on distinct sides of the transmembrane helix, which is predicted by molecular modeling to spontaneously assemble into trimers and dimers. In human B cells, these mutations impair ligand-dependent (C172Y) and ligand-independent (A181E) TACI multimerization and signaling, as well as TACI-enhanced proliferation and/or IgA production. Genetic inactivation of TACI in primary human B cells impaired survival of CpG-activated cells in the absence of ligand. These results identify the transmembrane region of TACI as an active interface for TACI multimerization in signal transduction, in particular for ligand-independent signals. These functions are perturbed by CVID-associated mutations.

INTRODUCTION

TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) is a TNF receptor superfamily member that binds the ligands BAFF (B cell activation factor of the TNF family, BLyS) and APRIL (a proliferation-inducing ligand) (Bodmer et al., 2002; Mackay and Schneider, 2009). In the TNF family, trimeric ligands stimulate membrane-bound receptors, but the form under which receptors respond to ligands is not fully characterized. Receptor dimers, as seen in a crystal structure of TNFR1, or pre-assembled trimers may undergo ligand-induced conformational changes or form multimeric networks when engaged by trimeric ligands to initiate intracellular signaling cascades (Chan et al., 2000; Naismith et al., 1995, 1996). Pre-oligomerization of receptors has also been described for Fas, CD40, TRAILRs (Clancy et al., 2005; Siegel et al., 2000; Smulski et al., 2013, 2017a), and TACI (Garcia-Carmona et al., 2018; Lee et al., 2009). Pre-oligomerization involves the first cysteine-rich domain (CRD) in the extracellular portion of TNFR1, Fas, CD40, and TRAILRs, while ligand binding is mediated by the second and third CRDs. TACI is a special case as it exists as two splice variants, TACI-L with two CRDs and TACI-S lacking CRD1 (hereafter called TACI ∆CRD1) (Hymowitz et al., 2005). Despite its single CRD, TACI ∆CRD1 can bind its ligands, oligomerize with itself or TACI-L, and support plasma cell development (Garcia-Carmona et al., 2015, 2018). This excludes that TACI oligomerization can be controlled by CRD1 only. TACI ∆CRD1 is thus similar to BAFFR, a receptor whose single CRD appears to promote both oligomerization and BAFF binding (Pieper et al., 2014).

TACI is expressed by activated human B cells, marginal zone B cells, switched memory B cells, and plasma cells. Upon ligand binding, TACI supports T cell-independent type II antibody responses by inducing class-switch recombination and differentiation into plasma cells (Castigli et al., 2005; Salzer et al., 2005). When BAFF binds to TACI and BAFFR, TACI enhances processing of BAFF by the metalloprotease ADAM10, which limits BAFF-regulated B cell survival (Smulski et al., 2017b). TACI is...
also cleaved by ADAM10, releasing a soluble decoy receptor form (sTACI) that can neutralize BAFF and APRIL (Hoffmann et al., 2015). Elevated numbers of B cells in Tacic mice can be explained by lack of sTACI decoy activity (Bulow von et al., 2001). Also, patients with primary antibody deficiencies harboring TACI mutations affecting expression or ligand binding have elevated BAFF levels and autoimmunity (Kreuzaler et al., 2011; Lee et al., 2009; Salzer et al., 2009). Higher levels of BAFF also correlate with autoimmunity in persons with a mutation that increases the half-life of BAFF mRNA (Steri et al., 2016), a phenotype that is similar to BAFF transgenic mice (Mackay et al., 1999). Thus, by regulating the availability and strength of BAFF-induced survival signals, TACI can control the size of B cell populations. However, switched memory B cells do not depend on BAFF or APRIL for survival, despite expression of both BAFFR and TACI, because they are unaffected or even increased in patients treated with BAFF-neutralizing antibodies or with TACI-Fc (Baker et al., 2020; Stohl et al., 2012; van Vollenhoven et al., 2011; Wallace et al., 2009).

In humans, mutations affecting the structure and function of TACI, such as C104R and A181E, are associated with CVID, the most frequent primary immunodeficiency disorder (Yazdani et al., 2020). Mutation of a single TACI allele is already a risk factor for CVID (Salzer et al., 2009). The TACI C104R mutation disrupts a conserved cysteine residue in CRD2, abolishing ligand binding but not surface expression of TACI (Lee et al., 2009; Salzer et al., 2009). As the C104R variant decreases the decay activity of sTACI and blunts T-independent B cell responses, CVID patients with this mutation have increased B cell numbers combined with defective T-independent immune responses.

The A181E mutation in the transmembrane (TM) domain of TACI is encoded by the SNP rs72553883, which has an allele frequency of 0.5%-0.6%. The mutation prevents neither surface expression nor ligand binding. Carriers of the A181E mutation have lower levels of anti-pneumococcal polysaccharide IgM and IgG and lower titers of natural anti-E. coli antibodies (Castigl et al., 2005; Jabara et al., 2017). The corresponding mutation (A144E) in a transgenic mouse model impaired constitutive and ligand-induced NF-κB signaling in B cells (Lee et al., 2009). In mice knockin for Taci A144E, virtually no TACI was detected and a CVID-like phenotype characterized by severely impaired responses to T-independent antigens and to S. pneumoniae infections was observed. In the heterozygous state, TACI expression was lower than in the wild type (WT) (Jabara et al., 2017). The SNP rs751216929 encoding the variant C172Y in the TM domain has an allele frequency of 0.02% and was also found in CVID patients (Mohammadi et al., 2009). C172Y and A181E have been reported to disturb APRIL-induced activation of NF-κB and NFAT (Fried et al., 2011).

Structural reports have highlighted an intrinsic role of the TM domains of TNFRs in the formation of dimers (p75NTR) (Nadezhdin et al., 2016), trimers (Fas and TNFR1) (Chou, 2020; Fu et al., 2016), or dimers of trimers (DR5) (Pan et al., 2019). Thus, understanding the structural basis of TM oligomerization may shed light on the mechanism for signal transduction and the impact of disease-associated mutations in this region. Moreover, B cell development and responses of mice carrying the A144E mutation, and of humans carrying the A181E or C172Y variants, differ from those of TACI-deficient mice or C104R carriers, especially for B lymphocytosis and autoimmunity, suggesting that specific activities of TACI may be linked to its TM region. Here, we provide evidence that the TM region of TACI regulates ligand-independent assembly into trimers and to a lesser extent into dimers, to activate NF-κB and support TLR9-induced proliferation of human B cells. Mutations C172Y and A181E disturbed ligand-dependent as well as ligand-independent functions of TACI, providing a mechanistic explanation for the association of these mutations with primary antibody deficiencies and pointing to a potential ligand-independent role of TACI in regulating B cell homeostasis.

RESULTS

TACI TM assembly model

Evidence that TACI TM self-interacts was first obtained by photo-inducible crosslinking. A TACI-EYFP fusion protein metabolically labeled with a photo-activatable leucine, among others in leucine residues of the TM domain, was specifically crosslinked after a short UV pulse. Crosslinked TACI migrated predominantly as trimers, but also as dimers and higher-order oligomers, possibly hexamers (Figure 1A).

Analysis of the TM helix of TACI showed that residues A181 and C172 point in opposite directions, suggesting they could be part of different association interfaces (Figure 1B). Three programs used to predict dimerization of single-span TM regions, TMDOCK (Lomize and Pogozheva, 2017), PREDDIMER
(Polyansky et al., 2014), and CATM (Mueller et al., 2014) proposed a dimerization interface involving C172 in TACI of humans and other mammals (Figures 1C and S1A–S1C). A Monte Carlo simulation with implicit membrane models predicted that mutation C172Y disturbs a closer association of both helices, most probably by steric hindrance caused by the tyrosine residue (Figure 1D).

Modeling of TM regions into trimers requires pre-existing structural information. The TM region of lysosome-associated membrane protein type 2a (LAMP-2a) (Rout et al., 2014), which is 33% identical to TACI, was selected to model the trimeric assembly of the TACI TM domain (Figure 1B). In this model, the A181 residue faces toward the inner side of TACI trimers. A Monte Carlo simulation predicted that the trimeric assembly of the TM region is destabilized by the A181E variant (Figure 1F). Monte Carlo simulations of other naturally occurring or rationally designed mutations in the TM region of TACI demonstrated anomalies in all cases, but not necessarily with the expected impact on the assembly mode, probably because substitutions also affect protein-lipid interactions that contribute to correct insertion and tilt angle of TM helices in lipid bilayers (Figure S1D).

Thus, crosslinking and modeling studies suggest that the TACI TM domain may assemble into dimers and trimers, with residues C172 and A181 participating to dimeric and trimeric interfaces, respectively (Figures 1G and 1H), similar to the published NMR structure of the TM domain may assemble into dimers and trimers, with residues C172 and A181 participating to dimeric and trimeric interfaces, respectively (Figures 1G and 1H), similar to the published NMR structure of the TM domain of DR5/TRAILR2 that contains both dimeric and trimeric associations in a dimer-trimer network (Pan et al., 2019).

**The TACI TM domain organizes mainly as trimers through the A181 interface in simulated membranes**

Results of modeling studies were challenged using coarse-grained molecular dynamic simulations. This technique reduces the complexity of a system (proteins, lipids, and water) by treating groups of atoms as “beads” that respect the chemical properties of the molecules, allowing simulations with minimal loss of structural information but high gain of statistical power. For example, all backbone atoms of an amino acid residue are combined in a backbone bead, while side chains are fitted into additional beads (Marrink et al., 2007; Monticelli et al., 2008; Siewert et al., 2019). Thirty-six copies of TACI TM domains (residues 156–190, WT, A181E, or C172Y) were evenly distributed in the x/y plane of a membrane patch of modeled phospholipids and randomly oriented along the z axis (Sica and Smulski, 2021). Their evolution was recorded along 7.9 μs of simulation (Figure S2A). Three main parameters were recorded: the distance and position at which any helix contacts a reference helix (measured by a distance and by angle α) and the relative orientation of contacting helices (measured by angle β). This was measured repeatedly for each of the 36 helices with a time resolution of 50 ns and cumulated data were plotted into radial density maps (showing the most frequently occupied locations on helices) and angular maps (showing relative orientations of interacting helices) (Figures 2A–2D). Two highly populated spots labeled as T2 and T3 were observed on the A181 side of the reference helix (T1) at α angles of 150° and 220°, respectively (Figure 2B). Beta angles of the interacting helices at positions T2 and T3 were about 120° and 250°, fitting well with predicted angles of 120° and 240° for assembly along a 3-fold symmetry axis (Figure 2D). When all interaction data from 3 to 7.5 μs were compiled in a contact matrix, residues V160, V163, Y164, V174, C177, F178, and A181 were identified (Figure 2E), which corresponded well to those identified in the trimeric homology model of TACI (Figure 1E). Moreover, this model superimposed well with five randomly selected trimers generated in the simulation (root-mean-square deviation of 2.1 ± 1.7 Å) (Figure 2F).

Simulation data thus indicate a strong tendency of TACI TM helices to assemble as trimers through the A181 side.

The two main spots in the angular map were then extracted using OPTICS clustering, which finds density-based clusters in data of varying density (Ankerst et al., 1999). Three parameters were analyzed: (1) which of the 36 chains were incorporated...
within a trimer, (2) with which partners, and (3) how long did these interactions last. In this simulation, 33 out of the 36 helices were incorporated into 16 different and dynamic combinations of trimers, some of which were transient while others lasted for several μs (Figures 2G and 2H).

According to the models in Figure 1C, dimers were expected to be observed with an α angle of 50° and a β angle of ~180° (Figure 2B). There was a minor spot at 50° in the radial density map (Figure 2B). This spot was smaller than peaks T1 and T2 because dimers with the “correct orientation” formed less frequently than trimers (2 dimers versus 11 trimers displaying a cumulated association time >1 μs); but, then, these dimers could last for several μs just like trimers (Figures 2J and 2K). These stable dimers superimposed well with the dimeric TACI model of Figure 1C (root-mean-square deviation of 2 ± 1.4 Å) (Figure 2L).

The analysis of the A181E variant showed an anti-clockwise rotation of the two main spots in the radial density map (α angle) and a rotation of their relative orientations (β angle), suggesting that trimers may still be the preferred assembly mode with differences probably due to repulsion or steric hindrance between glutamic acids (Figures S2B–S2D). Trimer formation in TACI C172Y was also altered to some extent, even though C172 is not directly part of the trimerization interface (Figures S2B–S2D). Dimeric associations were affected in both TACI variants, with a slight distance increase between helices for A181E (1.1 versus 0.9 nm) and a wider distribution of locations and orientations in this region for C172Y. In accord with this simulation data, TACI A181E formed less trimers than WT in UV crosslinking experiments, while TACI C172Y formed less dimers (Figure S2E).

Taken together, these results consolidate the potential of TACI to assemble as a trimer via contacts on the A181 side of the TM helix and, to a lesser extent, as a dimer by contacts on the C172 side. Mutations A181E and C172Y disturb but do not completely abolish these associations.

**Oligomerization and interactions of TACI polypeptides chains**

To test the extent to which TM domains control TACI interactions in living cells, TACI variants tagged with fluorescent proteins were prepared (Figure 3A). Yellow fluorescent protein (YFP) fused to the intracellular C terminus allowed visualizing membrane expression of TACI WT, A181E, and C172Y expressed by lentiviral gene transfer in BJAB Burkitt’s lymphoma cells (Figure 3B). It also allowed detection of Förster resonance energy transfer (FRET) between closely positioned YFP- and RFP-labeled TACI (Figures 3C and 3D). BJAB cells were selected because they express no endogenous TACI. In addition, the chromosomal BAFFR alleles were inactivated by CRISPR-Cas9 mutagenesis to suppress interference in BAFF stimulation assays. FRET studies were also performed in transiently transfected HEK293T cells as an independent experimental setting.

Addition of BAFF 60-mers to BJAB cells expressing WT TACI-YFP (amino acid residues 1–293, hereafter called WT TACI) and TACI-RFP further increased FRET+ cells. This ligand-induced increase was consistently seen for all TACI mutants able to bind BAFF when monitored under conventional or heterozygous-like conditions (i.e., when WT and mutant FRET partners were co-expressed). As expected, no ligand-induced increase was observed with TACI C104R that cannot bind BAFF via CRD2 and with TACI lacking the extracellular domain (Flag-TACI 152–293, hereafter called TACI ΔECD). For reasons that remain unclarified, one exception was TACI ΔCRD1 that did not respond to BAFF under conventional conditions (although it did in heterozygous conditions). The other exception was TACI C172Y under conventional conditions, suggesting that C172 directly participates to ligand-induced multimerization and possibly signaling (Figures 3D–3G).

In the absence of BAFF, percentages of FRET+ cells were identical for TACI WT and ΔECD in both BJAB and HEK293T cells, underscoring an important role of the TM domain for spontaneous interactions (Figures 3D and S3A). Percentages of FRET+ cells were reduced for TM domain mutations A181E and, to a lesser extent, C172Y, in conventional and heterozygous-like conditions in BJAB and HEK293T cells, except for TACI C172Y in BJAB cells under conventional conditions (Figures 3E, 3G, and S3C–S3G). A contribution of the structural integrity of CRD1 and of CRD2 to TACI associations is suggested by lower percentages of FRET+ cells in BJAB cells expressing TACI ΔCRD1 or TACI C104R. This was, however, not observed in HEK293T cells (Figures 3D and S3A). It is possible that a relatively modest contribution of the extra-cellular domain to self-association could be masked by higher expression levels in HEK293T cells.

BJAB BAFFR-ko cells co-expressing CD40-YFP and -RFP fusion proteins were included as controls for the FRET analyses. The spontaneous association of CD40 was readily detected and further increased after addition of soluble CD40L. CD40 and TACI did not associate so that the percentage of FRET+ cells...
Cell Reports

A. Auto-activation

B. Ligand-induced activation at 0.8 ng receptor

C. Auto-activation

D. Domain structure of TACI

E. Auto-activation

F. Western Blot Analysis

<table>
<thead>
<tr>
<th>BAFF 60-mer</th>
<th>BJAB wt</th>
<th>BJAB-TACI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (min)</td>
<td>0 5 10 15 30 60 120</td>
<td>0 5 10 15 30 60 120</td>
</tr>
<tr>
<td>WB: p-IkBa</td>
<td>50 50 50 50 50 50 50</td>
<td>50 50 50 50 50 50 50</td>
</tr>
<tr>
<td>WB: IkBa</td>
<td>37 37 37 37 37 37 37</td>
<td>37 37 37 37 37 37 37</td>
</tr>
<tr>
<td>WB: Actin</td>
<td>50 50 50 50 50 50 50</td>
<td>50 50 50 50 50 50 50</td>
</tr>
</tbody>
</table>

(legend on next page)
remained low and unresponsive to either CD40L or BAFF 60-mer (Figure 3H).

To further support the role of the TM region as a hub for TACI oligomerization, Flag-tagged TACI or Flag-tagged TACI-YFP lacking the extracellular portion and part of the intracellular domain were co-expressed with VSV-tagged TACI and immunoprecipitated using an immobilized anti-Flag antibody. VSV-tagged TACI co-immunoprecipitated with both constructs (Figure 3), indicating again major contributions of the TM domain and no essential function of the extracellular domain for TACI self-interactions (Figure 3).

In conclusion, the FRET and co-immunoprecipitation approaches corroborate crosslinking and modeling studies. The ligand-independent oligomerization depends strongly on the TM region, with a possible context-dependent contribution of the extracellular domain. Variants C172Y and A181E in the TM region reduce TACI self-association in BJAB and HEK293T cells. Thus, the dominant phenotype of TACI mutants C104R, A181E, and C172Y in CVID patients (Castigli et al., 2005; Fried et al., 2011; Jabara et al., 2017; Salzer et al., 2005, 2009) could be explained if activation of TACI requires both self-association of the TM domains and ligand binding.

The TACI TM domain regulates ligand-independent and ligand-dependent NF-κB signaling

BAFF binding to TACI enhances clustering (Figure 3) and activates the canonical NF-κB pathway (Gülow von and Bram, 1997; Xia et al., 2000). As TACI can assemble spontaneously, we tested in HEK293T cells with an NF-κB luciferase reporter if TACI alone could activate NF-κB, or in the presence of co-transfected full-length ligands. TACI WT indeed activated NF-κB in the absence of ligand, and this signal could be further increased by co-transfection of either BAFF or APRIL in conditions where receptor alone did not saturate the response (0.8 ng of plasmid). The trimerization-defective TACI A181E was impaired for ligand-independent signaling, but responded to ligands, while TACI C172Y signaled normally in the absence of ligand, but responded poorly to BAFF and almost not at all to APRIL (Figures 4A and 4B). Similar results were obtained for the AP1 signaling pathway (Figures S4A and S4B). Careful titrations of both TACI and BAFF over wide concentration ranges showed that WT TACI had the strongest ligand-dependent signals at low receptor levels (0.05 ng of plasmid), while TACI A181E required intermediate receptor levels (0.2–0.8 ng of plasmid) for similar effects. TACI C172Y had poor overall responses to BAFF, suggesting that C172 is involved in transmitting BAFF effects (Figures S4C–S4E).

TACI WT, A181E, and C172Y ΔECD behaved like the corresponding full-length versions for ligand-independent signaling, although with slightly reduced efficiency (Figures 4C and 4D). Similarly, there was no significant difference in ligand-independent signaling for full-length TACI, TACI ΔCRD1, and TACI ΔECD, although the latter tended to be less active (Figures 4D and 4E). Unsurprisingly, the intracellular domain was required for signaling. It was unaffected by fusion to a YFP tag, and it was unable to produce any signal when expressed alone without TM domain (Figures S4F–S4H). Together, these results indicate that the intracellular domain of TACI must be multimerized at the plasma membrane via self-association of the TM domain to transmit ligand-independent signals. We do not exclude a contribution of the extracellular domain.

To further evaluate the differential impact of TM TACI mutants in ligand-dependent and -independent signals, mutations A181E and C172Y were combined. The double mutant not only displayed further decreased oligomerization in FRET analysis but was also unable to transmit any ligand-independent or -dependent signals (Figures S5A–S5C). It was, however, expressed normally and, despite reduced surface expression, could bind to both BAFF and APRIL (Figures S5D and S5E).

As phosphorylation of IκBα by the IKKs is an essential early step in the activation of canonical NF-κB (Yamamoto and Gaynor, 2004), we tested the impact of mutations A181E or C172Y on TACI-induced phosphorylation of IκBα. Five minutes after BAFF addition, IκBα was strongly phosphorylated in BJAB cells expressing WT TACI, then declined within 30 min (Figure 4F). IκBα was not phosphorylated in cells expressing TACI C172Y, while TACI A181E still allowed IκBα phosphorylation but less than WT TACI (Figure 4F).

In summary, the C172Y and A181E mutations have distinct effects on TACI signaling. The C172Y mutation, which seems to disturb mainly the dimerization of TACI, did not diminish ligand-independent activation of NF-κB by TACI but prevented its activation in response to ligand binding. In contrast, the A181E mutation, which was predicted to have a direct impact on trimerization, reduced ligand-independent activation but still allowed ligand-dependent activation of NF-κB, albeit at a lower extent than WT. Combining both mutations abolished signaling.

Figure 4. TACI TM domain regulates ligand-independent and ligand-dependent activation
(A) NF-κB-luciferase reporter assay after transfection of the indicated amounts of plasmids for TACI WT, C172Y, or A181E in the absence of ligand (auto-activation).
(B) NF-κB-luciferase reporter assay after transfection of 0.8 ng of TACI WT, A181E, or C172Y with the indicated amounts of BAFF (left) or APRIL (right) plasmid.
(C) Similar to (A) for the transfection of TACI variants (TACI, A181E, and C172Y) in which the extracellular domain was replaced by a Flag tag (152–293), in the absence of ligand (auto-activation).
(D) Cartoon of different TACI variants used in the NF-κB reporter experiments.
(E) Similar to (A) for the comparison of WT TACI full length, TACI-ΔCRD1 and TACI-ΔECD, in the absence of ligand (auto-activation). All plasmids have been controlled for similar expression levels at the concentrations used in the experiments. Plots show one representative experiment performed in duplicate out of three independent experiments.
(F) TACI-negative BJAB cells, and clones of BJAB stably transduced with TACI WT, A181E, and C172Y were incubated with 200 ng/mL of BAFF 60-mer for the indicated time periods. NF-κB activation was monitored by western blot in whole-cell extracts for IκBα phosphorylation and degradation. The experiment shown is representative of three independent ones. See also Figures S4 and S5.
Overexpression of TACI enhances proliferation of TLR9-activated B cells
As ligand-independent oligomerization of TACI activated NF-κB, and because NF-κB family proteins regulate central steps in B cell activation and proliferation (Gilmore et al., 2004; Kober-Hasslacher et al., 2020; Roy et al., 2019), we reasoned that overexpression of TACI might enhance or even induce proliferation of human B cells. To test this hypothesis, human B cells were transduced with lentiviral expression vectors encoding different TACI-YFP fusion proteins. A signaling-deficient form of TACI-YFP lacking the intracellular TRAF- and Myd88-binding regions (1–223, hereafter called TACI ΔICD) was used as negative control, while BAFFR-YFP was used as control of a similar receptor with different signaling modalities. To prevent ligand-induced TACI activation, TACI-Fc at 100 ng/mL was added to neutralize BAFF and APRIL potentially produced in the system.

Lentiviral transduction of resting human B cells with a TACI-YFP expression vector did not induce proliferation of YFP-positive cells, but markedly increased CpG- or TRIL9-induced proliferation of B cells (Figures 5A, 5B, and 5G). After 4 days of culture, the ratio of proliferating versus resting B cells was, on average, 7.0 ± 1.6 for cells overexpressing TACI-YFP, versus 2.9 ± 1.2 and 1.1 ± 0.3 for TACI ΔICD-YFP and BAFFR-YFP cells, respectively (Figure 5C). The ratio was intermediate for mutants A181E-YFP (4.0 ± 1.4) and C172Y-YFP (4.4 ± 1.6), but still significantly lower compared with TACI-YFP (Figure 5C).

Overexpression of TACI ΔECD-YFP also enhanced the proliferation significantly above the level observed with TACI ΔICD-YFP. As TACI ΔECD assembled with itself and with WT TACI (Figures 3D, 3F, and 3I), and because it activated an NF-κB luciferase reporter plasmid (Figure 4C), it can be assumed that contacts between the TM domains is required for ligand-independent signaling. However, as the proliferative response of cells overexpressing TACI ΔECD was weaker than that of WT TACI, interactions between extracellular domains of TACI or between TACI and other proteins, including heparan sulfate proteoglycans, might play a role in regulating proliferation rates. The proliferation rates expressing the ligand binding-deficient mutant C104R were like those of cells expressing WT TACI-YFP, thus supporting the hypothesis that TACI can induce ligand-independent signals to enhance proliferation of TLR9-activated B cells.

CVID patients carrying TACI mutations have typically very low serum IgA titers and very few circulating IgA-positive switched memory B cells (Castigli et al., 2005; Pan-Hammarström et al., 2007; Romberg et al., 2015; Salzer et al., 2005, 2009). Differentiation of naive B cells overexpressing the different forms of TACI into IgA+ plasmablasts in the absence of ligand was observed for cells expressing WT TACI, TACI ΔCRD1, or TACI C104R, and was reduced for TACI A181E but not or less for C172Y (Figure 5D). This suggests that those forms of TACI which oligomerize, like the WT protein, can induce ligand-independent signals, which allowed class-switch recombination of CpG-activated B cells. IgA production was impaired by the TM region mutant A181E, which mainly affected ligand-independent signals in BJAB and HEK293T cells, but not or less by mutant C172Y, which mainly affected ligand-dependent signals. In TACI ΔECD, IgA production was impaired, suggesting again a role for the extracellular domain in ligand-independent B cell activation (Figure 5D).

TACI-mediated ligand-independent signals sustain proliferation of CpG-activated primary human B cells
As the expression levels of lentivirally transduced TACI were 10- to 20-fold higher than those of endogenous TACI, the increased proliferation of TACI-expressing B cells might have resulted from clusters of overexpressed TACI molecules. We therefore tested if inactivation of endogenous TACI would reduce proliferation of CpG-activated human B cells.

B cells were electroporated with ribonucleoprotein (RNP) complexes formed from Cas9 and TACI gRNAs (gRNA 5–8), cultured overnight, and activated with CpG, which induced TACI expression in about half of the cells within 3 days (Figure 6A). TACI-Fc was added in the culture medium to block TACI activation by endogenously produced or serum-derived BAFF and/or APRIL. Electroporation with gRNA 8/Cas9 RNPs significantly decreased but did not abolish TACI expression, which is not unexpected given that already expressed TACI protein can survive gene inactivation (Figures 6A, 6B, and 6D). This partial reduction of TACI protein levels correlated with lower numbers of cell divisions in TACI-positive cells, while the TACI-negative B cell population, which was less responsive to CpG, was unaffected (Figures 6C–6E). Cells electroporated with gRNA 6/Cas9 RNP complexes neither reduced TACI expression nor inhibited CpG-induced B cell proliferation (Figures 6A–6D). The correlation between decreased levels of surface TACI and decreased proliferative response to CpG was statistically significant (Figure 6C). Thus, decreased TACI expression correlated with lower proliferation and/or survival rates, supporting the hypothesis that TACI can modulate the proliferative response of B cells by ligand-independent signaling.

DISCUSSION
Several TNF receptor family members assemble into multimers through interactions of pre-ligand assembly domains (PLAD) that are usually located in the first extracellular cysteine-rich domain (CRD1) (Chan et al., 2000; Clancy et al., 2005; Pieper et al., 2014; Siegel et al., 2000; Smulski et al., 2013). For TACI, other parts of the protein must be involved as TACI ΔCRD1 can still associate with full-length TACI (Garcia-Carmona et al., 2018). The TM domains in different TNFRSF members stabilize homotypic interactions and play active roles in signal transduction (Chou, 2020; Fu et al., 2016; Nadezhdin et al., 2016; Pan et al., 2019), providing a potential explanation for why TACI mutations C172Y and A181E in the TM region disturb downstream functions (Fried et al., 2011; Hammarström et al., 2000; Jabara et al., 2017) and associate with primary antibody deficiencies (Castigli et al., 2005; Fried et al., 2011; Garibyan et al., 2007; Salzer et al., 2005, 2009).

The results of our combined experimental and bioinformatic investigations on TACI TM domain are summarized in a model (Figure S7). Two different sides of the TACI TM domain serve as interfaces for TACI assembly into oligomers. Trimerization through the
side defined by A181 is stable and accounts for most of the observed FRET signals, while dimerization through the side defined by C172 would be induced and/or stabilized by ligands. Indeed, BAFF spontaneously forms 3-mers that can further interact with each other via a loop region called the flap (Vigolo et al., 2018). Flap-flap interactions are too weak to form stable BAFF 6-mers in solution but may cooperate with weak contacts between C172 dimerization interfaces to form signaling-competent hexameric TACI TM structures. Such hexameric TACI TM structures may also form by “random” associations of TACI trimers via other interfaces at higher TACI concentrations. These alternative interfaces were suggested in the simulation data.

Figure 5. Overexpression of TACI enhances proliferation of TLR9-activated B cells

(A) Human B cells labeled with CellTrace Violet were transduced with lentiviral vectors encoding various TACI-YFP fusion proteins or BAFFR-YFP and activated with 0.1 μM CpG.

(B) After 5 days of cultivation, proliferation of YFP⁺ or YFP⁻ CD19⁺ cells shown in the red and blue gates, were analyzed by flow cytometry determining the percentage of dividing (CTV⁻) and non-dividing (CTV⁺) cells. Percentages of YFP⁺, CTV⁺, and CTV⁻ cell populations are shown.

(C) Ratio of the percentage of proliferating/non-proliferating YFP⁺ B cells. YFP fusion proteins were made with full-length WT TACI, TACI-ΔCRD1, TACI-C104R, TACI-C172Y, TACI-A181E, TACI-ΔECD, TACI-ΔICD, and BAFFR. The insert on the right depicts TACI expression levels of cells expressing YFP fusion proteins and by controls after 4 days of cultivation. p values are indicated.

(D) Percentage of IgA⁺ cells after 4 days of cultivation. p values are indicated. ns: non significant. See also Figure S6A.
displaying weakly populated spots at angles different from the A181 and C172 interfaces. Mutating hydrophobic A181 to a larger polar residue (A181E) perturbs trimeric interactions making TACI less fit to signal. Mutating small polar C172 to a bulky residue (C172Y) would instead impair formation of larger networks of trimers via the C172 interface and decrease response to ligands (Figure S7). Similar to TACI, the TM domain of DR5/TRAILR2 has distinct dimerization and trimerization faces, allowing formation of dimers of trimers and thus the expansion of an interaction network essential for signal transduction (Pan et al., 2019). PLAD interactions in the extracellular domain may favor hexamer formation and signaling in the presence of ligand or stabilize an inactive dimeric state in the absence of ligand.

Overexpression of TACI promoted CpG-induced proliferation of primary human B cells as well as the formation of IgA+ B cells in the absence of BAFF and APRIL. The C172Y and A181E mutations reduced the proliferation-enhancing activity and A181E also reduced the formation of IgA+ cells. Although interactions between the transduced mutant and endogenous WT TACI may have masked mutant-specific effects, a fully functional TM domain seems to be required for the formation and/or expansion of IgA+ B cells. This stimulatory function of TACI could be relevant for the generation of secretory IgA against commensal bacteria in the gut through a T-independent program (Grasset et al., 2020).

In the human population, mutations in the TACI gene occur mainly in the heterozygous state, implying that dimeric or trimeric complexes of TACI can consist of a mix of WT and mutants. With regard to ligand-induced signaling, dominant-negative mutants, such as C104R, would inactivate most of these complexes, while other mutants, such as A181E, would still allow ligand-induced signaling. These differences would explain the incomplete penetrance observed for heterozygous mutations C172Y or A181E (Pan-Hammarström et al., 2007; Salzer et al., 2009), and the dominant-negative role of C104R in primary antibody deficiencies (Garibyan et al., 2007; Romberg et al., 2015). However, none of our results provided sufficient evidence to undoubtedly confirm or exclude such dominant-negative effects. With regard to
ligand-independent signals, activation of NF-κB measured by a luciferase reporter was unimpaired for TACI C172Y (Figure 4A), yet co-stimulation of CpG-induced proliferation in primary B cells was lower in response to transduced TACI C172Y than WT (Figure 5C). This difference might be explained if signals other than NF-κB also participate in the proliferative response.

CAML interacts with TACI, at least in yeast two-hybrid experiments (Bülow von and Bram, 1997), raising the question of whether this may involve TM domain interactions. CAML, which has been renamed “guided entry of tail-anchored proteins factor CAMLG,” has been characterized by cryoelectron microscopy as an essential component of a membrane insertion complex for tail-anchored proteins in the endoplasmic reticulum (McDowell et al., 2020). Should CAML interact with the TM domain of TACI (although TACI is not a tail-anchored protein), this may not necessarily be relevant to TACI signaling.

The activation of TLR9 induces TACI expression (Morbach et al., 2016). In turn, co-activation of TACI and TLR9 enhances cell division and differentiation into plasma cells (Chinen et al., 2011; Groom et al., 2007; Martinez-Gallo et al., 2013; Ng et al., 2006; Ozcan et al., 2011; Romberg et al., 2015). Inactivation of TACI in CpG-activated primary B cells reduced TACI expression and impaired cell division. As partial inactivation of TACI impaired CpG-induced proliferation, individual differences in TACI expression might contribute to individual differences in responses to T-independent antigens. Ligand-independent TACI could be especially relevant to T-independent immune responses as TLR7/8- or TLR9-derived signals strongly increase the expression of TACI.

Based on its ligand-independent proliferation-enhancing activity, TACI would fulfill criteria of a proto-oncogene. TACI is elevated in B lymphoma cells (Chiu et al., 2007; Thaler et al., 2017; Yurchenko and Sidorenko, 2010), in gliomas where its level correlates with tumor grade (Pelekanou et al., 2013), and in breast cancer (Kampa et al., 2020). It has been proposed as a new therapeutic target in triple-negative breast cancer (Abou-Elfadl et al., 2020). But, different from typical proto-oncogenes, TACI lacks an enzymatic activity that could be changed by mutations into a constitutive-active receptor. Moreover, TACI is constitutively shed by ADAM10, and the part that remains stuck in the plasma membrane is further processed by γ-secretase (Hoffmann et al., 2015; Meinl et al., 2018). Differently from Notch, which is processed in the same way (Groot and Vooijs, 2012; Radtke et al., 2010), the intracellular part of TACI is degraded. The real oncogenic potential of TACI may thus result from the balance between TACI and ADAM10 levels.

In addition to activated B cells, TACI is constitutively expressed by switched memory B cells and plasma cells, which co-express TACI together with the related receptor BCMA. Survival of naïve B cells (Batten et al., 2000; Warrat et al., 2009) and of plasma cells (O’Connor et al., 2004), but not of switched memory B cells (Benson et al., 2008), depends on BAFF- and/or APRIL-induced pro-survival signals. As switched memory B cells express TACI and BAFFR, but as their survival does not depend on BAFF or APRIL (Furie et al., 2011; van Vollenhoven et al., 2011; Wallace et al., 2009), it would be of interest to determine whether they require TACI, and in particular ligand-independent TACI signals, for their survival and homeostatic proliferation.

In summary we provide evidence that the TM domain of TACI can auto-associate via two distinct interfaces to regulate ligand-dependent and -independent signaling. This association modality can explain the distinct effects of CVID-associated mutations located in this region and provides a model for the ligand-independent activity of TACI in regulating the proliferation of B cells in T-independent immune responses and the homeostasis of switched memory B cells.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Cell lines
  - Primary cell cultures
- **METHOD DETAILS**
  - Immunoprecipitations
  - Luciferase reporter assay
  - Photo-inducible TACI cross-linking
  - Lentiviral gene transfer into primary human B cells
  - Knock out in primary human B cells
  - Molecular modelling
  - Coarse grained molecular dynamic simulations
  - Radial density
  - Contact maps
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2022.110583.

ACKNOWLEDGMENTS

We thank Beate Fischer for excellent technical assistance. This work was supported by grants from the Swiss National Science Foundation (310030_156961 and 31003A_176256 to P.S.), by project funding from Merck KGaA (to P.S.), by the Deutsche Forschungsgemeinschaft (DFG) through P06 of the TRR130 (to H.E.), and by the Hans-Hench-Stiftung and Fondo para la Investigación Científica y Tecnológica (FONCYT) PICT-2018-01107/PICT-2019-00642 (to C.R.S.).

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS

H.H. is employee of Merck KGaA. Other authors declare no competing interests.


# STAR Methods

## Key Resources Table

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse anti-CD19 APC/Cy7 (clone HIB19)</td>
<td>Biolegend</td>
<td>Cat# 302218, RRID: AB_314248</td>
</tr>
<tr>
<td>Rat anti-TACI APC (clone 1A1)</td>
<td>Biolegend</td>
<td>Cat# 311912, RRID: AB_2565423</td>
</tr>
<tr>
<td>Goat F(ab')2 anti-IgD FITC</td>
<td>SouthernBiotech</td>
<td>Cat# 2032-02, RRID: AB_2687521</td>
</tr>
<tr>
<td>Mouse anti-human CD27 PE (clone M-T271)</td>
<td>Biolegend</td>
<td>Cat# 356406, RRID: AB_2561825</td>
</tr>
<tr>
<td>Mouse anti-β-actin (clone AC15)</td>
<td>Sigma Aldrich</td>
<td>Cat# A5441, RRID: AB_476744</td>
</tr>
<tr>
<td>Anti-GFP antibody</td>
<td>Sigma Aldrich</td>
<td>Cat# 11814460001, RRID:AB_390913</td>
</tr>
<tr>
<td>ANTI-FLAG(R) antibody produced in rabbit</td>
<td>Sigma-Aldrich</td>
<td>Cat# F7425, RRID:AB_439687</td>
</tr>
<tr>
<td>Mouse Anti-VSV Glycoprotein Monoclonal Antibody, Unconjugated, Clone P5D4</td>
<td>Sigma-Aldrich</td>
<td>Cat# V5507, RRID:AB_261877</td>
</tr>
<tr>
<td>Phospho-I B (Ser32) (14D4) Rabbit mAb antibody</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2859, RRID:AB_561111</td>
</tr>
<tr>
<td>Mouse Anti-IkappaB-alpha Amino-terminal Antigen Monoclonal Antibody, Unconjugated, Clone L35A5</td>
<td>Cell Signaling Technology</td>
<td>Cat# 4814, RRID:AB_390781</td>
</tr>
<tr>
<td>Mouse Anti-TACI (ATA1) monoclonal antibody</td>
<td>Merck (Darmstadt, Germany)</td>
<td>250.14.1.1.4.3</td>
</tr>
<tr>
<td>Peroxidase-AffiniPure Donkey Anti-Mouse IgG (H+L) antibody</td>
<td>Jackson ImmunoResearch Labs</td>
<td>Cat# 715-035-150, RRID:AB_2340770</td>
</tr>
<tr>
<td>Peroxidase-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody</td>
<td>Jackson ImmunoResearch Labs</td>
<td>Cat# 711-035-152, RRID:AB_10015282</td>
</tr>
<tr>
<td>Biotin anti-human CD27 antibody</td>
<td>BioLegend</td>
<td>Cat# 302804, RRID:AB_314296</td>
</tr>
<tr>
<td><strong>Chemicals, peptides, and recombinant proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAFF 60-mer</td>
<td>Produced in house/Adipogen</td>
<td>ps2565/AG-40B-0112-3010</td>
</tr>
<tr>
<td>hTACI (aa 31–110)-hlgG1 Fc (aa 245–470)</td>
<td>(Kowalczyk-Quintas et al., 2019)</td>
<td>N/A</td>
</tr>
<tr>
<td>L-Methionine</td>
<td>Sigma-Aldrich</td>
<td>Cat# 64319</td>
</tr>
<tr>
<td>L-Photo-Leucine</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 22610</td>
</tr>
<tr>
<td><strong>Critical commercial assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neon Transfection System 10 μL Kit</td>
<td>Thermo Fischer Scientific</td>
<td>Cat# MPK1096</td>
</tr>
<tr>
<td>jetPEI</td>
<td>Polyplus transfection</td>
<td>Cat# 101-10N</td>
</tr>
<tr>
<td>NEBuilder HiFi DNA Assembly Cloning Kit</td>
<td>New England Biolabs</td>
<td>Cat# E5520S</td>
</tr>
<tr>
<td>PolyFect Transfection Reagent</td>
<td>Qiagen</td>
<td>Cat# 301105</td>
</tr>
<tr>
<td>ANTI-FLAG(R) M2 Affinity Gel antibody</td>
<td>Sigma-Aldrich</td>
<td>Cat# A2220, RRID:AB_10063035</td>
</tr>
<tr>
<td>MojoSort™ Human Naïve B Cell Isolation Kit</td>
<td>Biolegend</td>
<td>Cat# 48068</td>
</tr>
<tr>
<td>Cell Trace Violet</td>
<td>Thermo Fischer Scientific</td>
<td>Cat# C34571</td>
</tr>
<tr>
<td>Naive B Cell Isolation Kit II, human</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-091-150</td>
</tr>
<tr>
<td><strong>Experimental models: Cell lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BJAB</td>
<td>DSMZ</td>
<td>Cat# ACC-757, RRID:CVCL_5711</td>
</tr>
<tr>
<td>HEK293T</td>
<td>DSMZ</td>
<td>Cat# ACC-635, RRID:CVCL_0063</td>
</tr>
</tbody>
</table>

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Pascal Schneider (pascal.schneider@unil.ch).

Materials availability
Plasmids generated in this study are available upon request to the lead contact. Please use the “ps” identification code listed in the plasmid Table S2.

Data and code availability
- Maps of plasmids used in this study and data used for graphs have been deposited on the Zenodo repository, DOI 10.5281/zenodo.6122280. "Zenodo: https://zenodo.org/record/6122280#.YjOgErgo8lI"
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines
Human embryonic kidney HEK293T cells were grown in DMEM medium (Gibco) supplemented with 10% foetal calf serum. The human Burkitt lymphoma B cell line BJAB (BAFFR+/TACI-) was obtained from the DSMZ German Collection of Microorganisms and Cell Cultures and grown in IMDM medium (Gibco) supplemented with 10% foetal calf serum. The identity of BJAB cells was confirmed by microsatellite sequencing (cell line typing service, Microsynth, Balgach, Switzerland). BJAB lines expressing different forms of TACI, CD40 or BAFF were generated by retroviral and lentiviral transduction with respective expression vectors.

Primary cell cultures
Human B cells were either isolated from the blood of healthy donors or from leucocyte reduction systems and grown in IMDM medium (Gibco) supplemented with 10% foetal calf serum. All experiments with human cells were approved by the Ethics commission of the Albert-Ludwigs-University Freiburg through approvals 251/13, 147/15, and 169/13.
METHOD DETAILS

**FRET** – ECFP/EYFP experiments were performed using a LSRII flow cytometer instrument (BD Biosciences). EYFP signal was recorded using the 488 nm laser with a 530/30 filter, ECFP signal was recorded using the 405 nm laser with a 450/50 filter and FRET signal was recorded using the 488 nm laser with a 585/42 filter. HEK293T cells were transiently transfected with ECFP and EYFP fusion receptors and analysed 16–20 h post-transfection. Positive FRET cells were gated using an ECFP-EYFP fusion protein as positive control and a co-transfection of ECFP and EYFP as negative control according to (Schneider et al., 2014). EYFP/RFP experiments were performed using a FORTESSA flow cytometer instrument (BD Biosciences). EYFP signal was recorded using the 488 nm laser with a 530/30 filter, RFP signal was recorded using the 561 nm laser with a 610/20 filter and FRET signals were recorded using the 488 nm laser with a 624/15 filter.

**Immunoprecipitations**

1 × 10⁶ 293T cells transiently transfected with Flag-TACI constructs and untagged or EYFP-tagged constructs were used for immunoprecipitations with anti-Flag resin (Sigma-Aldrich) as described in (Schneider et al., 2014). Immunoprecipitates and input fractions were analysed by SDS-PAGE on 12% acrylamide gels and western blot analysis.

**Luciferase reporter assay**

HEK293T cells were cultured in 96 well plates at 3 × 10⁵ cells/ml in 100 μl of medium. After 24 h, cells were transfected with a mix of vectors containing: EGFP (transfection efficiency control) (7 ng), control renilla vector (7 ng), NF-κB or AP1 firefly luciferase reporter vector (7 ng), various TACI constructs (from 0.05 to 12.8 ng), and full-length BAFF or APRIL (from 0.05 to 12.8 ng), and empty plasmid to reach 70 ng/well of total DNA, using Polyfect transfection reagent (Qiagen). After 24 h, cells were lysed and expression of firefly and renilla luciferases were detected as described (Schneider et al., 2014).

**Photo-inducible TACI cross-linking**

HEK293T cells were seeded at 2 × 10⁵ cells/ml in a 12 well plate in 1 mL of medium. 24 h latter, medium was removed, cells were washed twice with PBS and cultured in 1 mL of leucine/methionine-free medium (DMEM-LM; Thermo Scientific) supplemented with 10% FCS (dialyzed against PBS), 30 mg/mL of L-methionine (Sigma-Aldrich) and 4 mM of L-Photo-Leucine (Thermo Scientific). Transfection was performed 24 h later using JetPrime (Polypus transfection) according to the manufacturer’s protocol. After 24 h of incubation, medium was removed and cells were washed twice with PBS and left in 250 μL PBS. Cells were exposed for 75 min to UV-light (365 nm), placing the lamp 2 cm on top of the plate (without lid). Whole cell lysates were prepared and analysed by western blot anti-TACI.

**Lentiviral gene transfer into primary human B cells**

Lentiviral vectors were constructed using the NEBuilder kit of NEB by integrating PCR fragments encoding TACI wildtype or mutant cDNA into pNL-CEF-YFP, a derivative of pNL-CEF-GFP in which GFP was replaced by YFP or RFP (Sic et al., 2014). Naïve IgG + CD27- B cells were isolated by depleting other cells using the MojoSort™ Human Naive B Cell Isolation Kit of Biolegend supplemented with biotinylated anti-human CD27 antibodies at 4 μg/ml (clone O323, Biolegend). Cells were labelled with Cell-Trace Violet (Thermofisher), plated into U96 wells at 3 × 10⁵ cells/ml, transduced with lentiviral vectors as described before (Kienzler et al., 2013; Pieper et al., 2014) and activated with 0.1 μM CpG in IMDM containing 10% FCS. After 4 days, cells were isolated and analyzed by flow cytometry.

**Knock out in primary human B cells**

Naïve B cells were isolated from peripheral blood lymphocytes of healthy donors using MACS Naïve B-cell Isolation Kit II (Miltenyi Biotec). After isolation, naïve B cells were electroporated using the Neon transfection system (Invitrogen, Carlsbad, CA, USA) (1x, 20 ms at 2300 V) with recombinant Cas9-gRNA complexes following manufacturer’s instructions (Integrated DNA technologies (IDT), Iowa, USA) and transfected in Iscove’s Modified Dulbecco’s Medium (IMDM; ThermoFisher, Waltham, MA, USA) supplemented with 20% foetal calf serum (FCS), 100 units/ml penicillin, 100 μg/ml streptomycin, 1 μg/ml insulin, 2.5 μg/ml apo-transferrin, 1% non-essential amino acids, 2 mM glutamine and 1 μg/ml reduced glutathione as described earlier (Kienzler et al., 2013). After 24 h, cells were rinsed with PBS, 2 mM EDTA and loaded with 1.25 μM cell trace violet for 20 min at 37°C. Afterwards, cells were washed with IMDM, 10% FCS and resuspended at 1.5 × 10⁶ cell/ml in IMDM, 10% FCS, 50 nM CpG. Cells were incubated at 37°C in 6.6% CO₂ for 3 days. Finally, cells were analysed by flow cytometry.

**Molecular modelling**

Monte Carlo simulation was performed with Hippo software (Biowerkzeug) using OPLS-AA force field (Kaminski et al., 2001; William L Jorgensen et al., 1996) and generalized born implicit membrane solvation model (J. P. Ulmschneider et al., 2007a; M. B. Ulmschneider et al., 2007b). Distance between C alpha of the c-terminal residue L186 was used to estimate proximity between TM helixes along a simulation period of 10⁶ steps. All images were generated using PyMOL Molecular Graphics System, Version 1.0, Schrödinger, LLC.
Coarse grained molecular dynamic simulations

The structures of the TM domains of TACI (residues 156 to 190), and its variants C172Y and A181E, were constructed as helices using the software PyMOL and then converted to Martini coarse-grain topology using the martinize.py tool (de Jong et al., 2013). The starting system consisted of a box of $25 \times 25 \times 10$ nm with 36 individual CG helices evenly spaced in the XY-plane with their axes oriented in the Z axis as previously described (Sica and Smulski, 2021). The 36 helices were placed in a lipid bilayer on the XY-plane using the INSANE (INSert membrANE) tool, and randomly oriented around Z. The lipids were composed of DOPC and DLPC (7:3) equally distributed on both sides of the membrane. The coarse-grained chain L correlates with 12:0 (lauric) and 14:0 (myristic) saturated fatty acids, whereas chain O correlates with C16:1(9c) (palmitoleic) and C18:1(9c) (oleic) unsaturated fatty acids, allowing to build a model of a biological fluid membrane. The system was completed with CG water beads and consisted of 36 peptides, 1700 lipids, 26000 waters and 600 ions (150 mM concentration), totalling 48000 particles. Simulations were carried out with the GROMCAS package version 2016.5 (Abraham et al., 2015) using the Martini v2.1 forcefield (Marrink et al., 2007). After the initial steps of minimization and equilibration the systems were simulated with a 20 fs time step at 310 K and 1 bar using the velocity rescaling thermostat of Busi et al. (Bussi et al., 2007) and the semi-isotropic Parrinello-Rahman barostat. Every system was simulated for at least 7 µs.

Radial density

First, the centroid (C) of every helix was computed between a defined central backbone (BB) atom (i) and two consecutive BB atom at each side in the sequence ($C_i = (r_{i-2}+r_i+r_{i+2})/5$, where r is the XYZ-coordinate of the atom). Second, the unit bisection vector was computed between the central (i) and adjacent BB atoms (i±1), according to the method of Khan to identify the helix orientation (Kahn, 2001). Third, a reference frame was defined with the centroid of the reference helix as origin and its orientation vector as unit X-vector, and the position of the centroids of the remaining 35 helices were computed. This procedure was repeated for all 36 helices present in the membrane patch along the indicated simulation time every 100 ns until the end of the simulated period. The scatter plot of the accumulated XY-centroids positions was transformed to a density map with ggplot implemented in R.

Contact maps

For each residue (i) of every helix (H) the number of contacts against all the other residues in the remaining helices, along the simulation time (T) was computed. A contact was defined when the BB atoms of two residues are located at XYZ-distance equal to or less than an arbitrary cut-off, as follows:

$$C_{ij}^{LK} = \begin{cases} 1, & \text{if } \|r_i^K - r_j^K\| \leq d_{\text{cutoff}} \\ 0, & \text{if } \|r_i^K - r_j^K\| > d_{\text{cutoff}} \end{cases}$$

where i and j are the residue number in the peptide sequence (i = {1,...,j,...,N}), and H and K are the helices analysed (H= {1,...,K,...,36}). Thus, the number of contacts (NC) for every residue i against each residue j in the remaining (K) helices were computed as:

$$NC_{ij} = \sum_T \sum_{k=1}^{K+H} C_{ij}^{LK}$$

QUANTIFICATION AND STATISTICAL ANALYSIS

ECFP-EYFP FRET experiments (Figure S3) and gRNA comparison (Figures 6B, 6D, 6E and S6B) were analysed using one-way ANOVA with Tukey’s multiple comparisons test. Proliferation (Figure 5C) and IgA class switch (Figure 5D) were analysed with one-way Brown-Forsythe and Welch ANOVA test (not assuming equal standard deviations), with Dunnett T3 multiple comparison test. EYFP-RFP FRET experiments ± BAFF (Figures 3D–3G) were analysed using two-way ANOVA with Tukey’s multiple comparisons test. Statistical analysis was performed using GraphPad Prism version 9.3.1 for Mac OS X, GraphPad Software, San Diego California USA, www.graphpad.com (ns p > 0.05).
Supplemental information

Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells

Cristian R. Smulski, Luyao Zhang, Malte Burek, Ariadna Teixidó Rubio, Jana-Susann Briem, Mauricio P. Sica, Eirini Sevdali, Michele Vigolo, Laure Willen, Patricia Odermatt, Duygu Istanbullu, Stephanie Herr, Marco Cavallari, Henry Hess, Marta Rizzi, Hermann Eibel, and Pascal Schneider
Supplemental information for manuscript
“Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells.”

Supplemental figure 1 (related to figure 1). TACI transmembrane assembly model.
A. Superposition of the top scored dimeric assembly models of TACI transmembrane region. TMDOCK model 1 (orange), CATM model 1 (black) and PREDDIMMER model 2 (grey). The root mean square deviations (RMSD) between these three structures are indicated at the bottom and indicate high similarities between models. B. Superimposition of dimeric structures of TACI transmembrane domain obtained by TMDOCK (orange) and PREDDIMMER (grey) for three randomly chosen mammals. C. Sequence alignment of TACI transmembrane sequence of several mammals and birds. The positions C172 and A181 are shaded in grey. Fully conserved residues are indicated with (*) at the bottom of the alignment. D. Monte Carlo simulation of the impact of different TACI TM variants (A181E, C172Y, F178L, L171R, V182G) annotated in the ClinVar database (NCBI) or rationally designed variants (L169Y, V174Y) on the dimeric and trimeric assembly.
Supplemental figure 2 (related to figure 2). TACI transmembrane domain organizes mainly as trimers through the A181 interface in simulated membranes.

A. Coarse-grain molecular dynamic simulation of 36 TACI transmembrane domains, wild type (wt) or with mutations A181E or C172Y embedded in a membrane formed of coarse-grained models of DOPC and DLPC (7:3) equally distributed on both sides of the membrane. Snapshots were taken at 0, 600 and 3000 ns. Helix distribution in the membrane is illustrated on the right. B. The most frequent organization in the XY plane is observed in the radial density maps (2D) where the position of each helix against the remaining 35 ones is computed all along the simulated period and superimposed at the centre of the quadrant. The centre of reference and orientations vectors were determined as illustrated in figure 2A. For the trimeric assembly, the most dense positions are indicated as T_2 and T_3 (T_3 being the centre of the reference helix). For the dimeric assembly, the most dense position is indicated as D_2 (D_1 being the centre of the reference helix). C. 3D version of the radial density map shown in panel (B). D. Angular map for the different TACI variants showing the preferred relative orientation (beta) for each position around the central helix (alpha). The orientations vectors were determined as illustrated in figure 2C. Scales in panels B and C correspond to the 2D kernel density estimation. E. Crosslinking of TACI WT, A181E and C172Y fused to EYFP in HEK 293T cells labelled with a photo-activatable leucine analogue. Whole cell extracts were analysed by western blotting using anti-GFP antibodies that recognize EYFP fused to TACI.
Supplemental figure 3 (related to figure 3). Oligomerization and interactions of TACI polypeptide chains.

A. Oligomerization analysis by Förster Resonance Energy Transfer (FRET) of TACI truncations schematized in panel (B). In all panels FRET+ corresponds to an EYFP-ECFP fusion protein, while FRET- corresponds to the co-transfection of EYFP and ECFP. At least 9 independent experiments were averaged for each truncation. B. Scheme of the different TACI truncations used in this figure. TACI ΔCRD1 (1-223 Δ21-67→W) corresponds to TACI-S (isoform 2). C. FRET analysis of wt TACI ΔICD-EYFP with wt TACI, C104R, C172Y or A181E ΔICD-ECFP. CD40 ΔICD-ECFP was used as a negative control. At least 5 independent experiments were averaged for each pair. D. FRET analysis of TACI wt and C104R, both ΔICD. E. FRET analysis of TACI wt and C172Y, both ΔICD. F. FRET analysis of TACI wt and A181E, both ΔICD. G. FRET analysis of TACI wt, C172Y and A181E-ΔICD in all combinations. CD40 was used as a negative control.
Supplemental figure 4 (related to figure 4). TACI transmembrane domain regulates ligand-independent and ligand-dependent activation.

A. AP1-luciferase reporter assay after transfection of the indicated amounts of plasmids for TACI wt, C172Y or A181E in the absence of ligand (auto-activation). B. AP1-luciferase reporter
assay after transfection of 0.8 ng of TACI wt, A181E or C172Y with the indicated amounts of APRIL (left) or BAFF (right) plasmid. C-E. Activation of a NFκB-luciferase reporter with the indicated amounts of TACI wt, A181E or C172Y plasmids and variable amounts of BAFF plasmid, normalized to a condition without TACI and BAFF. Bottom panels show ligand-dependent activation only, calculated as a ratio to the no-ligand condition (auto-activation) for each receptor concentration used. F. NFκB-luciferase reporter assay after transfection of the indicated amounts of plasmids for full length wt TACI, full length TACI fused to EYFP, TACI C104R and TACI intracellular domain (ICD) in the absence of ligand (auto-activation). G. Scheme of the plasmids used in panels (F and H). H. NFκB-luciferase reporter assay after transfection of the indicated amounts of plasmids coding for wt TACI (full-length) and TACI ΔICD (lacking the TRAF binding site). The assay was performed in the absence of ligand (Mock) or with co-transfection of 5 ng/well of APRIL- or BAFF-coding plasmids.
Supplemental figure 5 (related to figures 4 and S4). TACI transmembrane domain regulates ligand-independent and ligand-dependent activation.

A. Oligomerization analysis by Forster Resonance Energy Transfer (FRET) of EYFP-fused TACI 1-223 in combination with ECFP-fused TACI wt, C172Y, A181E and the double mutant C172Y/A181E, all ΔICD. B. NFκB-Luciferase reporter assay titrating the indicated amounts of TACI wt, C172Y, A181E and the double mutant C172Y/A181E in the absence of ligand (auto-activation). C. NFκB-Luciferase reporter assay titrating the indicated amounts of BAFF on a single concentration (0.8 ng) of TACI wt, C172Y, A181E and the double mutant C172Y/A181E.
Smulski et al.                              Supplemental Information

(ligand-induced activation). D. Western blot analysis of TACI wt, C172Y, A181E and C172Y/A181E expression levels at the indicated concentrations. E. Flow cytometry detection of untagged TACI wt, C104R, C172Y, A181E and C172Y/A181E by an anti-TACI antibody or by Flag-BAFF or Flag-APRIL.
Supplemental figure 6 (related to figures 5 and 6). Overexpression of TACI does not induce cell division.

A. IgD- CD27- B cells were isolated by magnetic depletion of all other cells, labelled with cell trace violet (CTV) and transduced with a lentiviral vector encoding TACI-YFP. Cells were then either activated with 0.1 µM CpG (top row) or not (bottom row), cultivated for 4 days at 37°C and analysed by flow cytometry. The histogram overlays (right column) show CD19+ cells (left column) gated for TACI-YFP expression into YFP+ and YFP- cells. B. Mean fluorescence intensity (MFI) TACI expressed by B cells electroporated with a mock (Cas9/enhancer mix, control) or with four different TACI gRNA/Cas9 complexes. Dotted line corresponds to isotype control MFI levels. C. Correlation between TACI expression levels and the ratio...
proliferating/non-proliferating cells, following CRISPR/Cas9 inactivation of TACI in CpG activated primary B cells. Pearson correlation test p<0.0001.

**Supplemental figure 7 (related to figures 1 to 6). Working model of the implication of TACI transmembrane domain in signalling.**

A. Representation of a single TACI TM helix, top and side views. The dimeric interaction interface C172 is represented in cyan, and the trimeric interaction interface A181 in magenta. B. The favoured trimeric assembly of TACI TM region is mediated by the A181 interface. C. A labile and/or ligand-induced dimeric assembly of TACI TM region is mediated by the C172 interface. D. Mutation A181E affects but does not disrupt trimeric assembly. The C172 interface is not much impaired. E. Mutation C172Y disturbs dimeric interactions, and also affects trimeric interactions to some extent. F. Hexameric conformation of TACI TM region “oriented” via the C172 interface that would occur during ligand-dependent signalling. G. Hypothetic “random” hexameric conformation(s) of TACI TM region that may form during ligand-independent signalling. H. Model for ligand-induced oligomerization of TACI TM region. Weak FLAP interactions in BAFF and weak TACI interactions at the C172 interface may possibly stabilize each other to promote ligand-dependent signalling.
Table S1 (related to figures 6 and S6): TACI gRNA sequences:

<table>
<thead>
<tr>
<th>Name</th>
<th>IDT-ID</th>
<th>Sequence</th>
<th>PAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>TACI 5</td>
<td>Hs.Cas9.TNFRSF13B.1.AA</td>
<td>CTCGGGAAGGTACCAAGGAT</td>
<td>TGG</td>
</tr>
<tr>
<td>TACI 6</td>
<td>Hs.Cas9.TNFRSF13B.1.AB</td>
<td>TCATAGCCACCCCCGTCCAC</td>
<td>AGG</td>
</tr>
<tr>
<td>TACI 7</td>
<td>Hs.Cas9.TNFRSF13B.1.AC</td>
<td>GTTCTATGACCATCTCCTGA</td>
<td>GGG</td>
</tr>
<tr>
<td>TACI 8</td>
<td>Hs.Cas9.TNFRSF13B.1.AL</td>
<td>ACAATTGACAAACTCGGGA</td>
<td>AGG</td>
</tr>
</tbody>
</table>

IDT: Integrated DNA technologies (Iowa, USA).

Table S2 (related to figures 1, 3, 4, 5, S2, S3, S4 and S5): List and description of the plasmids used in the study.

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Designation</th>
<th>Protein encoded</th>
<th>Backbone</th>
</tr>
</thead>
<tbody>
<tr>
<td>ps015</td>
<td>Empty</td>
<td>Empty</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2155</td>
<td>EYFP</td>
<td>EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2156</td>
<td>ECFP</td>
<td>ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2565</td>
<td>His6-hBAFF</td>
<td>MRGSHHHHHHGS-h BAFF (134-285)</td>
<td>pQE9</td>
</tr>
<tr>
<td>ps2967</td>
<td>EYFP-ECFP</td>
<td>EYFP (1-239)-GGIETDGSIETDGG-ECFP (1-239)</td>
<td>pcDNA3.1 zeo</td>
</tr>
<tr>
<td>ps2460</td>
<td>hCD40 1-260-EYFP</td>
<td>hCD40 (1-260)-VDEFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2461</td>
<td>hCD40 1-260-ECFP</td>
<td>hCD40 (1-260)-VDEFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3260</td>
<td>hTACI 1-293-EYFP</td>
<td>hTACI (1-293)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3285</td>
<td>hTACI 1-293-ECFP</td>
<td>hTACI (1-293)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2252</td>
<td>hTACI 1-223-EYFP</td>
<td>hTACI (1-223)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2253</td>
<td>hTACI 1-223-ECFP</td>
<td>hTACI (1-223)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3281</td>
<td>hTACI 1-20 W 68-223-EYFP</td>
<td>hTACI (1-20)-W-(68-223)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3282</td>
<td>hTACI 1-20 W 68-223-ECFP</td>
<td>hTACI (1-20)-W-(68-223)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3250</td>
<td>Flag-hTACI 152-223-EYFP</td>
<td>HA signal-Flag-GPGQVQLQ-hTACI (152-223)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3242</td>
<td>Flag-hTACI 152-223-ECFP</td>
<td>HA signal-Flag-GPGQVQLQVD-hTACI (152-223)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2258</td>
<td>hTACI 1-223 C104R-EYFP</td>
<td>hTACI (1-223, C104R)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2259</td>
<td>hTACI 1-223 C104R-ECFP</td>
<td>hTACI (1-223, C104R)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3289</td>
<td>hTACI 1-223 C172Y-EYFP</td>
<td>hTACI (1-223, C172Y)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3291</td>
<td>hTACI 1-223 C172Y-ECFP</td>
<td>hTACI (1-223, C172Y)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2254</td>
<td>hTACI 1-223 A181E-EYFP</td>
<td>hTACI (1-223, A181E)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2255</td>
<td>hTACI 1-223 A181E-ECFP</td>
<td>hTACI (1-223, A181E)-EFPVAT-ECFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps4245</td>
<td>hTACI 1-293-EYFP</td>
<td>hTACI (1-293)-GPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4246</td>
<td>hTACI 1-293-RFP</td>
<td>hTACI (1-293)-GGSGSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4272</td>
<td>hTACI 1-21 68-223-EYFP</td>
<td>hTACI (1-21)-(68-223)-GPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4248</td>
<td>hTACI 1-21 68-223-RFP</td>
<td>hTACI (1-21)-(68-223)-GGSGSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4249</td>
<td>hTACI 1-293-EYFP A181E</td>
<td>hTACI (1-293 A181E)-GPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4250</td>
<td>hTACI 1-293-RFP A181E</td>
<td>hTACI (1-293 A181E)-GGSGSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4251</td>
<td>hTACI 1-293-EYFP C172Y</td>
<td>hTACI (1-293 C172Y)-GPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4252</td>
<td>hTACI 1-293-RFP C172Y</td>
<td>hTACI (1-293 C172Y)-GGSGSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4253</td>
<td>hTACI 1-293-EYFP C104R</td>
<td>hTACI (1-293 C104R)-GPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4254</td>
<td>hTACI 1-293-RFP C104R</td>
<td>hTACI (1-293 C104R)-GGSGSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ID</td>
<td>Description</td>
<td>HA Signal Sequence</td>
<td>Tag</td>
</tr>
<tr>
<td>-----</td>
<td>-------------</td>
<td>--------------------</td>
<td>-----</td>
</tr>
<tr>
<td>ps4255</td>
<td>hTACI 152-293-EYFP</td>
<td>HA signal-Flag-GPGQVQLQVD-{152-293}-EFPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4256</td>
<td>hTACI 152-293-RFP</td>
<td>HA signal-Flag-GPGQVQLQVD-{152-293}-GGSQSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4257</td>
<td>hCD40 1-260-EYFP</td>
<td>hCD40 (1-277)-DPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4258</td>
<td>hCD40 1-260-RFP</td>
<td>hCD40 (1-277)-DGSGSDPPVAT-RFP (1-237)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps4259</td>
<td>hTACI 1-223-EYFP</td>
<td>hTACI (1-223)-EFPVAT-EYFP (1-239)</td>
<td>pNL-CEF</td>
</tr>
<tr>
<td>ps2595</td>
<td>Flag-hTACI</td>
<td>HA signal-Flag-GPGQVQLQVD-hTACI (2-293)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2596</td>
<td>VSV-hTACI</td>
<td>HA signal-VSV-GPGQVQLQVD-hTACI (2-293)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps863</td>
<td>VSV-hBCMA</td>
<td>HA signal-VSV-GPGQVQLQ-hBCMA (2-184)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2165</td>
<td>AP1 luciferase</td>
<td></td>
<td>pGL3</td>
</tr>
<tr>
<td>ps1614</td>
<td>NfκB luciferase</td>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>ps1615</td>
<td>Renilla</td>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>ps515</td>
<td>EGFP</td>
<td>EGFP (1-239)</td>
<td>pcDNA3.1 zeo</td>
</tr>
<tr>
<td>ps1383</td>
<td>hTACI</td>
<td>hTACI (1-293)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2154</td>
<td>hTACI C104R</td>
<td>hTACI (1-293, C104R)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2172</td>
<td>hTACI C172Y</td>
<td>hTACI (1-293, C172Y)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps2153</td>
<td>hTACI A181E</td>
<td>hTACI (1-293, A181E)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps1861</td>
<td>hAPRIL</td>
<td>hAPRIL (1-250)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps544</td>
<td>hBAFF</td>
<td>hBAFF (1-285)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3709</td>
<td>Flag-hTACI 152-293-EYFP</td>
<td>HA signal-Flag-GPGQVQLQVD-hTACI (152-293)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3705</td>
<td>Flag-hTACI 152-293 A181E-EYFP</td>
<td>HA signal-Flag-GPGQVQLQVD-hTACI A181E (152-293)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3731</td>
<td>Flag-hTACI 152-293 C172Y-EYFP</td>
<td>HA signal-Flag-GPGQVQLQVD-hTACI C172Y (152-293)-EFPVAT-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps3704</td>
<td>hTACI 1-20 W 68-293-EYFP</td>
<td>hTACI (1-20)-W-(68-293)-EYFP (1-239)</td>
<td>PCR3</td>
</tr>
<tr>
<td>ps1301</td>
<td>VSV-hTACI ICD</td>
<td>MY-VSV-EF-hTACI (187-293)</td>
<td>PCR3</td>
</tr>
</tbody>
</table>

HA signal=MAIHYLILLFTAVRG  Flag=DYKDDDDK  VSV=TDIEMNRLGK

Plasmid maps and primary data for all graphs are available at DOI 10.5281/zenodo.6122280